Compare Trip.com Group Ltd (TCOM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs GeneDx Holdings Corp — how do they compare? Trip.com Group Ltd trades at $39.31 (market cap $26.04B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Trip.com Group Ltd is far larger — about 10.2× GeneDx Holdings Corp's market cap, and Trip.com Group Ltd pays a 0.42% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TCOM | WGS | |
|---|---|---|
Market Cap | $26.04B | $2.56B |
Sector | Consumer Cyclical | Technology |
52-Week High | $78.96 | $167.51 |
52-Week Low | $39.19 | $34.51 |
Enterprise Value | $18.64B | $2.60B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Trip.com (TCOM) trades at $40.50, down 1.29% with bearish technical signals despite strong fundamentals. The company reported robust 2025 results with $62.41B revenue and 53.34% net margin, though recent quarters show earnings misses. Valuation metrics appear attractive with P/E of 6.01 and EV/EBITDA of 3.21. However, the stock faces headwinds from a recent $770M Chinese antitrust penalty and declining cash flow trends.
The investment case balances deep value against regulatory risks. Analyst consensus remains bullish with $59.29 price target (47% upside), but technical weakness and China regulatory overhang create near-term uncertainty. Long-term growth prospects in travel recovery support the bull case, though investors should monitor Q2 2026 earnings due September 15 for confirmation of business momentum.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
